Tvardi Therapeutics

Contributing Author

Recent Articles by Tvardi Therapeutics

Jul-07	Tvardi Therapeutics' TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement TVRD +54.23% GlobeNewswire
May-21	Tvardi Therapeutics to Participate in Upcoming Investor Events TVRD -6.75% GlobeNewswire
May-08	Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update TVRD GlobeNewswire
Apr-02	Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium TVRD GlobeNewswire
Mar-31	Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update TVRD TVRD -5.66% GlobeNewswire
Feb-12	Tvardi Therapeutics to Participate in Upcoming Investor Conferences TVRD GlobeNewswire
Jan-08	Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference TVRD +8.74% TVRD +7.57% GlobeNewswire
Jan-08	Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights TVRD +8.74% GlobeNewswire